Novo Nordisk’s uphill battle in the counterfeit weight loss craze
As the popularity of weight-loss drugs like Ozempic soars, the Danish company has to manage seasoned criminals and international investigations to get results, finds Marisa Woutersen.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
25 June 2024 US drugmaker files six lawsuits over compounded tirzepatide products | At least five deaths associated with ‘generic’ Mounjaro, according to complaint | Fears over drug's 'unapproved' use for cosmetic weight loss.
12 March 2024 Danish drugmaker testing suspect products and assisting with legal cases | High demand and global shortages have driven surge in weight-loss drug fakes.